Ajinomoto Bio-Pharma Services

What Ajinomoto Bio-Pharma Services does

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization (CDMO) offering drug substance and drug product manufacturing services across small molecules, large molecules, gene therapy, oligonucleotides, and peptides. The company operates manufacturing sites in four countries — the United States (San Diego, though the aseptic fill/finish entity was divested in April 2025), Belgium (Wetteren, Balen, Mont Saint Guibert), Japan (Osaka), and India (Visakhapatnam) — providing services from pre-clinical development through commercial supply. Its core technology portfolio includes five proprietary platforms: AJICAP™ (site-selective antibody-drug conjugate bioconjugation), AJIPHASE® (hybrid solid-solution phase synthesis for oligonucleotides and peptides), Corynex® (Corynebacterium glutamicum-based recombinant protein expression), Crystalomics® (crystal suspension formulation for high-concentration biologics), and AJILITY™ (fast-track drug product manufacturing for vaccines and accelerated programs). The company holds multiple regulatory certifications including FDA approvals, European GMP from MHRA and HPRA, and FDA EIR for its India facility.

The company generates revenue through two primary streams: contract manufacturing services (project-based contracts and long-term manufacturing agreements with pharmaceutical and biotechnology companies across clinical and commercial phases) and technology licensing (proprietary platforms including AJIPHASE®, AJICAP™, and Corynex® licensed to other pharma companies). The company is a wholly-owned subsidiary of Ajinomoto Co., Inc. (TYO: 2802), a Tokyo-based conglomerate, and was formally constituted in October 2018 through the integration of Ajinomoto Althea (US biologics/fill-finish, acquired from Althea Technologies for ~$175M in 2013) and Ajinomoto OmniChem (Belgium small molecule API), with subsequent additions of GeneDesign (Japan, oligonucleotide CDMO, acquired 2016) and full ownership of Granules OmniChem (India, acquired 2020). The company targets both biotechnology companies developing novel therapeutics and pharmaceutical companies seeking contract manufacturing for APIs, drug products, and specialized modalities, with enterprise field sales teams and participation in industry conferences like the World ADC Summit as its go-to-market motion.

Name

Ajinomoto Bio-Pharma Services

Legal name

Ajinomoto Bio-Pharma Services

Website

https://ajibio-pharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ajinomoto Bio-Pharma Services is a global CDMO providing integrated contract development and manufacturing services across small molecules, large molecules, gene therapy, oligonucleotides, and peptides for pharmaceutical and biotechnology companies, operating from sites in the US, Belgium, Japan, and India.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Contract manufacturing services
• Pharmaceutical CDMO services
• Biologics manufacturing
• Antibody-drug conjugate manufacturing
• Oligonucleotide synthesis

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Full-service CDMO providing drug substance and drug product manufacturing services across clinical and commercial phases. Revenue generated through project-based contracts and long-term manufacturing agreements with pharmaceutical and biotech companies.
2. Technology Licensing: Licensing of proprietary technologies including AJIPHASE®, AJICAP™, and Corynex® to pharmaceutical companies for in-house development programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ajinomoto Bio-Pharma Services is a fully integrated Contract Development and Manufacturing Organization (CDMO) providing drug substance and drug product manufacturing services across small molecules, large molecules, gene therapies, oligonucleotides, and peptides. Services span pre-clinical through commercial phases, including process development, cGMP manufacturing, aseptic fill-finish, highly potent API and ADC production, and product quality/analytical testing, delivered through manufacturing sites in Belgium, the United States, Japan, and India. The company also licenses proprietary technology platforms (AJICAP™, AJIPHASE®, Corynex®, Crystalomics®) to pharmaceutical clients for in-house development programs.

Product overview

Ajinomoto Bio-Pharma Services is a fully integrated Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical manufacturing services across small molecule, large molecule, and advanced therapies. The company operates as a single unified platform combining multiple manufacturing capabilities and proprietary technology platforms including AJICAP™ (ADC bioconjugation), CORYNEX® (protein expression), AJIPHASE® (oligonucleotide/peptide synthesis), and Crystalomics® (crystal formulation). Services span from pre-clinical development through commercial supply, covering drug substance and drug product manufacturing, fill-finish, and analytical services across facilities in Belgium, United States, Japan, and India.

Differentiator

Problem solved

Functional benefit

Brands

• AJICAP™: Proprietary site-selective bioconjugation technology for ADC manufacturing enabling controlled payload conjugation and drug-to-antibody ratio tuning.
• AJIPHASE®
• AJILITY™
• Corynex®
• Crystalomics®

Products and services

• Small Molecule Manufacturing
• Large Molecule Manufacturing
• Highly Potent & ADC Services
• Oligo & Peptide Synthesis
• Gene Therapy Manufacturing
• Development Services
• Product Quality & Analytical Services
• AJICAP™
• Corynex®
• AJIPHASE®
• AJILITY™ Fast Track Platform

Quantifiable outcome

• Site-specific ADC with DAR of 2 achieved enhanced therapeutic window compared to stochastic ADCs
• +2 more outcomes

Named customers12 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

19 partnerships are on record, tiered core and minor.

• Piramal Pharma SolutionscoreStrategic or Co-development Partner · 16 April 2026Strategic collaboration for ADC development and manufacturing. Piramal refers applicable customers seeking ADC manufacturing technology to Ajinomoto Bio-Pharma Services and AJICAP™. Aji Bio-Pharma refers Piramal to customers as a potential CDMO for AJICAP™-based products. A separate Material Transfer Agreement (MTA) enables technology transfer between companies.
• Astellas Pharma Inc.coreTechnology or Integration · 31 October 2025Licensing agreement for biopharmaceutical development and manufacturing technology.
• Olon S.p.A.coreStrategic or Co-development Partner · 28 October 2025Strategic partnership to advance large-scale peptide and protein manufacturing.
• Gene ToolscoreStrategic or Co-development Partner · 21 October 2025Collaboration to expand access to PMO (phosphorodiamidate morpholino oligomer) therapeutics.
• RIBOMIC Inc.minorStrategic or Co-development Partner · 18 May 2025Successful extension of nucleic acid aptamer pharmacokinetics in joint research.
• NJ Bio, Inc.coreStrategic or Co-development Partner · 31 March 2025Collaboration to strengthen support for antibody-drug conjugate development.
• RIBOMIC Inc.minorStrategic or Co-development Partner · 27 December 2023Joint research agreement for nucleic acid aptamer pharmacokinetics extension.
• ExelixiscoreTechnology or Integration · 10 January 2023License agreement to discover and develop novel antibody-drug conjugates for cancer treatment.
• Bright Peak TherapeuticscoreStrategic or Co-development Partner · 29 March 2021Research collaboration and license agreement to create novel immunocytokines.
• Revance TherapeuticscoreStrategic or Co-development Partner · 22 December 2020Commercial manufacturing agreement for supply of DaxibotulinumtoxinA for Injection.
• DNDi (Drugs for Neglected Disease initiative)coreStrategic or Co-development Partner · 29 September 2020Strategic supply partnership for CpG-D35 oligonucleotide as part of combination therapy for cutaneous leishmaniasis. Supported by GHIT Fund.
• HumanigencoreStrategic or Co-development Partner · 27 May 2020Manufacturing agreement for fill finish supply of lenzilumab for COVID-19 Phase III clinical trials.
• CytoDyncoreStrategic or Co-development Partner · 5 May 2020Manufacturing partnership for drug product (leronlimab/PRO 140) used in COVID-19 clinical trials.
• Trio PharmaceuticalscoreStrategic or Co-development Partner · 30 April 2020Development collaboration to evaluate AJICAP™ for development of TRIObody Drug Conjugate™ (TDC) for cancer therapeutics.
• GeneDesigncoreOEM/ Whitelabel/ Licensing Partner · 9 April 2019GeneDesign joined Ajinomoto Bio-Pharma Services as wholly owned subsidiary. Provides oligonucleotide API development center in Osaka, Japan (2000 m²) with Class 100,000 clean area for cGMP manufacturing.
• XL-proteincoreStrategic or Co-development Partner · 18 December 2018Strategic alliance applying Ajinomoto's Corynex® expression system with XL-protein's PASylation® technology for plasma half-life extension of therapeutic compounds. Successfully produced PASylated GLP-1 variant at laboratory scale.
• Precision NanoSystemscoreStrategic or Co-development Partner · 23 October 2018Manufacturing collaboration agreement for GMP manufacturing of nanomedicines using PNI's NanoAssemblr™ Scale-Up system. Ajinomoto qualified PNI's GMP facilities and will provide clinical development services.
• US FDAcoreOthers · 22 September 2017Granules OmniChem Limited received Establishment Inspection Report (EIR) from US-FDA following successful on-site inspection for Pre-Approval Inspection of commercial custom manufactured product.
• Ajinomoto Co., Inc.coreOthers · 4 April 2013Ajinomoto Co., Inc. acquired Althea Technologies for approximately $175 million. Althea became Ajinomoto Althea, Inc. and later combined with OmniChem to form Ajinomoto Bio-Pharma Services.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Lonza Group: Swiss-headquartered global CDMO leader offering integrated small-molecule API, biologics, cell and gene therapy, and peptide manufacturing. Most directly comparable peer given breadth of modalities, proprietary tech platforms, and prior executive overlap (CEO David Enloe was previously Head of Viral Therapeutics at Lonza).
• Catalent: Large US-headquartered CDMO with biologics, fill-finish, ADC, and gene therapy capabilities (now owned by Novo Holdings). Closest comparable in integrated drug-substance/drug-product services and ADC/bioconjugation expertise.
• Samsung Biologics: Korean biologics CDMO offering large-scale mammalian cell culture, fill-finish, and aseptic manufacturing with global enterprise customer base. Comparable in large-molecule manufacturing scale and enterprise pharma customer wins.
• WuXi AppTec / WuXi STA: China-headquartered integrated CRDMO with extensive small-molecule API, biologics, oligonucleotide, and peptide manufacturing capabilities. Comparable end-to-end multi-modality CDMO model.
• Boehringer Ingelheim BioXcellence: German pharma's contract biologics manufacturing arm offering mammalian cell culture, microbial expression, and fill-finish. Comparable in large-molecule CDMO services and proprietary expression platforms.
• AGC Biologics: Global CDMO focused on microbial and mammalian biologics, gene therapy, and vaccine manufacturing. Comparable in proprietary expression platforms (Corynex® analog to AGC's microbial systems) and gene therapy modality.
• Bachem: Swiss-listed peptide and oligonucleotide CDMO with large-scale cGMP manufacturing. Highly comparable in oligo/peptide synthesis capabilities (AJIPHASE® overlap) and specialty API CDMO focus.
• CordenPharma: Europe-headquartered CDMO offering peptide, oligonucleotide, lipid, and small-molecule API manufacturing. Closely comparable in peptide/oligo synthesis services and high-potency API capabilities.
• Recipharm: European CDMO providing small-molecule API and biologics fill-finish services to pharma and biotech customers. Comparable in multi-site European footprint and integrated drug substance/drug product offering.

Broad incumbents

• Thermo Fisher Scientific (Patheon CDMO): Diversified life-sciences incumbent whose Patheon CDMO business offers small-molecule API, biologics, fill-finish, and clinical trial materials globally. Comparable as broad-based CDMO incumbent; less focused on ADC/oligo specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AjiBioPharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ajinomoto Bio-Pharma Services